pembrolizumab found to be safe with durable responses in advanced, non-small cell lung cancer
Published 9 years ago • 300 plays • Length 5:16Download video MP4
Download video MP3
Similar videos
-
4:25
new immunotherapy yields long-lasting responses in some patients with advanced m
-
0:51
pembrolizumab increases long-term survival in patients with advanced nsclc
-
6:00
ramucirumab plus pembrolizumab improves os in advanced nsclc
-
6:32
keynote trials show pembrolizumab benefited patients with advanced small cell lung cancer
-
5:37
phase iii trial shows pembrolizumab preferable to ipilimumab in advanced melanoma
-
7:13
first-line pembrolizumab plus chemotherapy for patients with advanced squamous nsclc: 3-year fol...
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
1:17:43
kcrs24 session six: immunotherapy advances in kidney cancer | kidneycan
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
5:51
pembrolizumab is safe and effective and substantially increases overall survival in ansclc patients
-
4:51
lung cancer trial for patients with prior response to immunotherapy
-
24:18
pembrolizumab is better than ipilimumab for advanced melanoma in phase iii trial
-
3:37
pembrolizumab plus chemo as firstline therapy for nsclc
-
6:10
pd-1 inhibitor pembrolizumab shows promising clinical activity for triple-negative breast cancer
-
9:33
five-year long-term overall survival for patients with advanced nsclc treated with pembrolizumab...
-
2:11
pembrolizumab works better than chemotherapy alone as initial treatment for nsclc
-
10:06
pembrolizumab for non-small cell lung cancer associated brain metastases
-
1:46
immunotherapy for lung cancer and trial of ramucirumab plus pembrolizumab
-
2:10
pembrolizumab, tumor response, and survival in advanced melanoma